Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel With or Without Vandetanib in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed gastric adenocarcinoma or gastroesophageal junction cancer~  * Metastatic disease~* Measurable disease~* No symptomatic CNS metastases~PATIENT CHARACTERISTICS:~Inclusion criteria:~* ECOG performance status 0-1~* Life expectancy ≥ 3 months~* ANC ≥ 1,500/µL~* Platelet count ≥ 100,000/µL~* Bilirubin ≤ 1.5 times upper limit of normal (ULN)~* Creatinine \< 1.5 times ULN OR creatinine clearance ≥ 50 mL/min~* Potassium ≥ 4.0 mEq/L (supplementation allowed) and ≤ the CTCAE grade 1 upper limit~* Magnesium normal (supplementation allowed) and ≤ the CTCAE grade 1 upper limit~* Calcium normal and corrected serum calcium ≤ the CTCAE grade 1 upper limit~  * In cases where the serum calcium is below the normal range, calcium (adjusted for albumin) normal OR ionized calcium normal~* ALT and AST ≤ 2.5 times ULN~* Alkaline phosphatase ≤ 2.5 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for up to 12 weeks after completion of study therapy~* Atrial fibrillation allowed if controlled by medication~* LVEF ≥ 45% by MUGA or ECHO~Exclusion criteria:~* Evidence of severe or uncontrolled systemic disease~* Any concurrent condition which makes it undesirable for the patient to participate in the trial or which would jeopardize study compliance, in the Investigator's opinion~* Uncontrolled infection~* Coagulopathy (including warfarin or anti-coagulant related) or bleeding disorder~* Peripheral neuropathy ≥ grade 2~* Clinically significant cardiac event, including myocardial infarction or New York Heart Association class II-IV heart disease within the past 3 months~* Presence of cardiac disease that, in the opinion of the Investigator, increases the risk of ventricular arrhythmia~* History of arrhythmia (i.e., multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) which is symptomatic or requires treatment (CTCAE grade 3) OR asymptomatic sustained ventricular tachycardia~* History of QTc prolongation as a result of other medication that required discontinuation of that medication~* Congenital long QT syndrome or a first degree relative with unexplained sudden death under 40 years of age~* Presence of left bundle branch block~* QTc with Bazett's correction that is unmeasurable or ≥ 480 msec on screening ECG~  * If a patient has QTc ≥ 480 msec on screening ECG, the screen ECG may be repeated twice (at least 24 hours apart)~ * The average OTc from the three screening ECGs must be \< 480 msec in order for the patient to be eligible for the study~* Hypertension not controlled by medical therapy (systolic blood pressure \[BP\] \> 160 mm Hg or diastolic BP \> 100 mm Hg)~* Currently active diarrhea (≥ grade 2) that may affect the ability of the patient to absorb vandetanib~* Previous or current malignancies of other histologies within the past 5 years, with the exception of cervical carcinoma in situ and adequately treated basal cell or squamous cell carcinoma of the skin~PRIOR CONCURRENT THERAPY:~* Recovered from all prior therapy~* At least 4 weeks since prior chemotherapy or radiotherapy~* No more than one prior chemotherapy regimen for metastatic disease~  * Prior adjuvant therapy, including chemoradiotherapy, allowed~* At least 2 weeks since prior palliative radiotherapy~  * Up to 3750 cGy palliative radiotherapy to the stomach allowed~* No prior therapy with docetaxel~* More than 30 days since prior investigational agents~* More than 4 weeks since prior and no concurrent or planned participation in another experimental drug study~* More than 4 weeks since prior major surgery and recovered~* More than 2 weeks since prior and no concurrent medication that may cause QTc prolongation or induce Torsades de Pointes~* No concurrent amiodarone~* No concurrent potent inducers of CYP3A4 function (e.g., rifampicin, rifabutin, phenytoin, carbamazepine, barbiturates, or Hypericum perforatum \[St. John wort\])~* No prior enrollment or randomization to treatment in the present study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: ACTIVE_COMPARATOR): Patients receive docetaxel IV once every 3 weeks.
- Arm II (Type: EXPERIMENTAL): Patients receive docetaxel IV as in arm I and oral vandetanib (100 mg) once daily.
- Arm III (Type: EXPERIMENTAL): Patients receive docetaxel IV as in arm I and oral vandetanib (300 mg) once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues